Why Did Orphazyme (ORPH) Shares Skyrocket As Much As 1387% Today?

Orphazyme A/S ORPH shares skyrocketed over 300% in the regular session on Thursday.

What Happened: Shares of the Denmark-based biopharmaceutical firm touched an intraday high of $77.77, running up 1,387%. 

There was no announcement made by the company on Thursday that could explain the volatility in shares which halted trading 20 times until the afternoon.

On Thursday, volumes touched 7.56 million shares whereas the average volume is 61,335.

Orphazyme shares ended Thursday’s regular session 302.4% higher at $21 and fell 9.29% in the after-hours trading to $19.05.

Why It Matters: On May 7, in the latest press statement put out by Orphazyme, it said its application for arimoclomol, which will be branded as MIPLYFFA for Niemann-Pick disease type C, is under priority review with the U.S. Food and Drug Administration — with the expected Prescription Drug User Fee Act action date of June 17.

On the same day, Orphazyme had announced that ORARIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) did not meet both primary and secondary endpoints.

In March, arimoclomol failed to meet primary and secondary endpoints in Phase 2 and 3 trials in inclusion body myositis patients.

Read Next: Biogen CEO Says $56,000 Annual Price For Alzheimer's Drug Reflects 'Two Decades Of No Innovation'

Posted In: arimoclomolMIPLYFFANiemann-Pick disease type CBiotechNewsSmall CapFDAMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.